Tools
Stock profile

PTC THERAPEUTICS, INC. (PTCT)

PTCT · Latest close $60.23 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$60.23
As of Nov 18, 2026
Tracked funds holding
3 of 149
2026 Q2 13F filings
Opened / added
1 / 0
vs previous quarter
Trimmed / exited
0
vs previous quarter

PTC THERAPEUTICS, INC. (PTCT) is held by 3 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund opening new positions versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $7.7M sold). Latest close $60.23 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 16, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-7.7M
Fundamentals
Revenue · FY2025
Red flags
screens flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

RTW Investments · OrbiMed Advisors · Polen Capital Management — 3 tracked funds hold PTCT. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 27 sales ($7.7M). Insider trading

Often held alongside

UroGen Pharma Ltd. (URGN) · Protagonist Therapeutics, Inc (PTGX) · Dianthus Therapeutics, Inc. /DE/ (DNTH) · Taysha Gene Therapies, Inc. (TSHA) · Guardant Health, Inc. (GH) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
RTW Investments5.39%7,746,415HELD Q3 filed Nov 16
OrbiMed Advisors0.07%49,100HELD Q3 filed Nov 16
Polen Capital Management0.02%24,916NEW Q3 filed Nov 13

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -26.0% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 18, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

89.5534.062024-11-182026-11-18

Closing prices (unadjusted for dividends), last 2 years — 502 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding382 of 8,857 filers
Long-only filers among them381
Change vs 2026 Q1+39 net · 368 entered · 329 exited
Shares reported, all filers100,298,101
Reported value, all filers$8.0B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryPharmaceutical Preparations (SIC 2834)
Revenue · FY2025$1.7B
Net income · FY2025$682.6M
Total assets · FY2025$2.9B
Shares outstanding83,544,284
Market cap (at latest close)$5.0B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Oct 27, 2026.

Short interest

Shares short · Oct 15, 20268,303,282
Share of shares outstanding9.94%
Days to cover7.59

Shares short at recent settlements — Jul 31, 2026: 10.6M · Aug 14, 2026: 10.2M · Aug 31, 2026: 9.8M · Sep 15, 2026: 9.7M · Sep 30, 2026: 9.2M · Oct 15, 2026: 8.3M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Oct 27, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Oct 27, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 27 sales by 3 insiders ($7.7M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 16, 2026Boulding Mark ElliottEXEC. VP AND CLOSell1,315$61.39$80.7KSEC filing
Nov 16, 2026Boulding Mark ElliottEXEC. VP AND CLOSell1,288$62.22$80.1KSEC filing
Nov 16, 2026Boulding Mark ElliottEXEC. VP AND CLOSell209$62.90$13.1KSEC filing
Oct 14, 2026SCHMERTZLER MICHAELSell2,118$59.52$126.1KSEC filing
Oct 14, 2026SCHMERTZLER MICHAELSell382$60.14$23.0KSEC filing
Oct 9, 2026Boulding Mark ElliottEXEC. VP AND CLOSell192$64.26$12.3KSEC filing
Oct 7, 2026SCHMERTZLER MICHAELSell2,447$63.38$155.1KSEC filing
Oct 7, 2026SCHMERTZLER MICHAELSell53$63.95$3.4KSEC filing
Oct 6, 2026Boulding Mark ElliottEXEC. VP AND CLOSell435$64.16$27.9KSEC filing
Oct 5, 2026Boulding Mark ElliottEXEC. VP AND CLOSell1,638$64.03$104.9KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Oct 9, 2026Boulding Mark ElliottOfficer192$12.3KOct 9, 2026SEC filing
Oct 7, 2026Section Six Partners, L.P.Affiliate of Director10,000$643.5KOct 7, 2026SEC filing
Oct 6, 2026Boulding Mark ElliottOfficer435$27.9KOct 6, 2026SEC filing
Oct 5, 2026Boulding Mark ElliottOfficer1,638$104.9KOct 5, 2026SEC filing
Sep 30, 2026STEELE GLENN JR MD PHDDirector12,000$781.9KSep 30, 2026SEC filing
Sep 9, 2026Section Six Partners, L.P.Affiliate of Director40,000$2.7MSep 9, 2026SEC filing
Aug 25, 2026Section Six Partners, L.P.Affiliate of Director50,000$3.6MAug 19, 2026SEC filing
Aug 19, 2026Michael SchmertzlerDirector50,000$3.6MAug 19, 2026SEC filing
Aug 17, 2026Boulding Mark ElliottOfficer2,813$201.7KAug 17, 2026SEC filing
Aug 4, 2026Klein Matthew B.Officer, Director10,292$705.8KAug 4, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
May 15, 2026JANUS HENDERSON GROUP PLCSC 13G/A7,193,4338.7%Mar 31, 2026SEC filing
May 15, 2026The Toronto-Dominion BankSC 13G/A3,025,9453.7%Mar 31, 2026SEC filing
Apr 30, 2026Vanguard Capital ManagementSC 13G4,284,4485.2%Mar 31, 2026SEC filing
Apr 29, 2026Vanguard Portfolio ManagementSC 13G4,871,3295.9%Mar 31, 2026SEC filing
Mar 27, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Feb 17, 2026JANUS HENDERSON GROUP PLCSC 13G4,851,3326.0%Dec 31, 2025SEC filing
Feb 13, 2026The Toronto-Dominion BankSC 13G4,138,2155.2%Dec 31, 2025SEC filing
Feb 10, 2026Wellington Management Group LLPSC 13G/A3,867,3804.8%Dec 31, 2025SEC filing
Feb 9, 2026STATE STREET CORPORATIONSC 13G4,206,1265.2%Dec 31, 2025SEC filing
Dec 4, 2025BlackRock, Inc.SC 13G/A11,904,69614.8%Nov 30, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 156 Lobbying Disclosure Act filings named this company as client, 2016–2026; most common issues: Health Issues (114), Medicare/Medicaid (57), Medical/Disease Research/Clinical Labs (42).

Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Financial Screens

· Greenblatt Magic Formula — High earnings yield and high return on capital together

Red Flags

· Excess Accruals (Sloan) — Sloan accruals ratio beyond ±25%

Key figures

· Greenblatt Magic Formula — Earnings yield: 11.1% · Return on capital: 63.7% · Combined rank: 12

· Excess Accruals (Sloan) — Accruals ratio: 28.7% · Net income: $682.6M · Operating cash flow: $711.2M · Investing cash flow: $-862.0M

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Also held by the tracked funds that hold PTCT — ranked by lift, the co-holding pattern described in Methodology: UroGen Pharma Ltd. (URGN) · Protagonist Therapeutics, Inc (PTGX) · Dianthus Therapeutics, Inc. /DE/ (DNTH) · Taysha Gene Therapies, Inc. (TSHA) · Guardant Health, Inc. (GH) · Natera, Inc. (NTRA).

Recent 8-K filings

FiledItemsSource
Nov 3, 20267.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing
Oct 29, 20262.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing
Sep 21, 20267.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

UroGen Pharma Ltd. (URGN) · Track Record: how the signals scored · Practice timing on PTCT

One email a week: the week’s new filings and research. Subscribe free

← PTC  ·  PTEN →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.